Nohla Therapeutics Inc.

  • CEO:
    Kathleen Fanning



Leading the development of universal, off-the-shelf cellular immunotherapies for patients with hematologic malignancies and other critical diseases.

Nohla Therapeutics Inc. (Nohla) is a clinical stage developer of universal donor cellular therapies for the treatment of patients with life threatening hematological disorders and other critical diseases. The Company’s proprietary Notch technology platform developed over the past two decades at Fred Hutchinson Cancer Research Center enables the ex vivo expansion and directed differentiation of cord blood stem/progenitor cells resulting in “off the shelf” universal donor cellular therapies. These products can be used on demand without the need for HLA matching and promote hematopoietic recovery in patients at risk for neutropenia after intensive chemotherapy and/or radiation treatment for critical diseases. Nohla is evaluating these “off the shelf” expanded cell products in several clinical settings including two lead programs with Dilanubicel (NLA-101), 1) a multi-center, randomized open label Phase IIb study in the setting of myeloablative cord blood transplant and 2) a multi-center, randomized global Phase II study in the setting of high dose chemotherapy for Acute Myelogenous Leukemia (AML).



Nohla was founded in November 2015 with licensed technology developed and studied for over two decades by Irv Bernstein MD and Colleen Delaney, MD, MSc, at Fred Hutchinson Cancer Research Center.


Nohla’s proven platform generates universal, off-the shelf therapies that enable improved clinical outcomes across a number of disease indications with the initial focus on high-risk hematological malignancies.

UTEC value up

Support for academic collaborations, business development objectives, and regulatory affairs especially in Japan.  
  • Proprietary Notch technology platform